Innovation and imitatio×₩₹λn,opportunity and challenge
Asia-Pacific Pharma IP Lead"₽er summit2019---14th-15th ←÷ NOV, Beijing CHINAOn March 19, 2019, the Wor≥☆"ld Intellectual Property Organization (WI♣£PO) published its global intellectual propertΩ¶©∏y report 2018.Asian innovators filed moΩ≤≤re than half of their internat₹¶ε$ional patent applicatiπ'™'ons through WIPO for the first time in•$€♦ 2018, with significant growth in China, India₩≈> and South Korea, the report noted.>'®÷ As a technology-intensive industry, pharma↔α'ceutical industry attac©₹hes great importance to ↓←§patent application and intellectual prope ₽☆rty protection.In recent year♥®™s, the size of the global pharmaceutical markΩ€β et has maintained a steady growth, with China, S<±outh Korea, India and other emergi≥→™ng markets presenting a raφ™δπpid growth momentum. Due π♣π↔to the different intellec÷®tual property policies of different coun♣tries, the strategic layout±≤ of global intellectual property, the di®Ω fferences of pharmaceutical intelleπλ"£ctual property policies of Asia-pacific £$≈♦countries, the patent☆∑ε review process, liti€εεgation procedures and Generic drug paφ♦★tent strategy have gradually bec"× ome the hot spots of the pharmaceutical intelleשΩctual property industry.In this ®₩context, the 2019 Asia-pacific Pharmaceutical↑ε IP Leader Summit will be hel↕≈d in Beijing on November 14-15, and will attract∞≥÷ more than 500 industry experts from domes×♣tic and foreign pharma $ceutical companies, biotechnology companies, g'≈overnments, associations, law firms, intellectuα£♠×al property agents and other companies to atten∞♠∏≥d.Agenda Framework:Section 1:Interpretation✘↓ of Policy: Development α₹of Pharmaceutical IP u♣₽×>nder the New Legislative Landscape Sect←☆ion 2:Pharmaceutical R&D Innovation an ↕δd IP Protection -- Global VisionSection∞¥ 3:Case Sharing of Pha≥ •rmaceutical Patent Invalidity, Infringement, ₩LitigationSection 4:Opportunities andα∞ challenges for generics companies under ✘the new situation HOTSPOT:ü Medical λπ€↑Policy Interpretation und$®er the Background of Patent Law Am₽←endmentü The innovation of Judicial Meε≥≈chanism Promotes the Development of Pharmac<ε₽eutical Intellectual Propertyü Inteδ"llectual Property Management Experience in Multi≥λnational Pharmaceutical Companies, Patent Layout×π Strategy, Litigation Str♦λ®ategyü he Data Pro¶•∞✘tection Regulations of Drug Test—New Eraü ✘β®γTrade Secrets and Patent Layout in the Medical₹© Fieldü Establishing Th™®λφe Internal Intellectual Property System under Th≠♥£e New Legislative Landscapeü&¥♠εδnbsp; Opportunities and Challenges of Pharmaceu↓≥φtical Enterprises under P<∏atent Term Compensation System-↔ γ€-- Global Vision and Its Implications for China✔α✔↕ü Latest Changes in Eurσβopean Patent Application and Review Proc≤↑♣eduresü Analysis of Hot Cases €♥♥≤of Recent Patent Invalidationü The ≈↔♣Procedure of American ÷§Pharmaceutical Patent litigation and its En <lightenment to Chinese Pharmace÷ utical Enterprises ü Applicati←on techniques and protection strategies for §→↓₹European and American biomedical paten&¥ εtsü Changes in standards for creative §₹review of patentsü&n←®Ω↕bsp; European, American and Japanese Medical Pat¥≠ ent Examination Cases and its implication∞₽s for DomesticPharmaceutical Companiesü R ★γecent Hot Patent Infringement $αCases Analysisü The Strategy of™±" Indian Generic Drug Companies in ™R&D and Pre-PAü&nbs♦≠p; How to avoid the Patent Trap in™✔β Generic Drug Developmentü&n™☆bsp; The Strategy of Generic Drug Companies☆$₩ to Enter the European and American M₩<arketsü Patentability in Europe, the Unite✘≥ d States and Chinaü Patent liti¥✔gation in Europeü&nbs♥¥₽p; Doubts around the Unified Patλλ✔↑ent Court (UPC) agreement and Brexitü ∑↓ Second medical use patentsComposition of par≈δ"→ticipants: Summit highlights:10+ Hot' ₩∏ topic20+ Authoritative speech5 0+ Indust∑¥ry media4 0+ BIC110+pharma &nb✔'€sp; company 500+專業(yè)參會(huì)嘉賓 &≈✘nbsp; ≈≥₹• &nb✔£sp; Professional participantsOffic←πial registration and consultation chann✔✘els:Contact:AnnPhone: σ☆021-65650305Email:Marketing@zenseegro≤up.comhttp://en.zenseegroup.com≠$/p/510934/